• Shuntong Kang, Wenyao Peng, Yuhao Zhu, Shiyao Lu, Min Zhou, Wei Lin, Wenfang Wu, Shu Huang, Liping Jiang, Xuan Luo, and Meichun Deng.
• Department of Biochemistry and Molecular Biology, School of Life Sciences, Central South University, Changsha, Hunan 410013, China; Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, China.
• Int. J. Antimicrob. Agents. 2020 May 1; 55 (5): 105950.

AbstractViral respiratory diseases such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) always pose a severe threat to people. First identified in late December 2019, a novel coronavirus (2019-nCoV; SARS-CoV-2) has affected many provinces in China and multiple countries worldwide. The viral outbreak has aroused panic and a public-health emergency around the world, and the number of infections continues to rise. However, the causes and consequences of the pneumonia remain unknown. To effectively implement epidemic prevention, early identification and diagnosis are critical to disease control. Here we scrutinise a series of available studies by global scientists on the clinical manifestations, detection methods and treatment options for the disease caused by SARS-CoV-2, named coronavirus disease 2019 (COVID-19), and also propose potential strategies for preventing the infection.Copyright © 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.

28 keywords...

hide…